Pharma Mar operates through Oncology and RNA Interference segments and was incorporated in 1986, based in Madrid, Spain. The company has achieved a 37.5% success rate in its investigations, far exceeding the 10.8% industry average, with eight compounds reaching clinical trials and three approved. The company operates through subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the US.
Cyborg Score Rationale
Pharma Mar invests 61.3% of revenues in R&D—nearly triple industry peers and well above the global pharmaceutical average of 30%. The company commands a rare marine-derived compound platform with exceptional clinical trial success rates. However, with $1.7B market cap and $189.2M revenue, scale remains constrained versus major competitors.
Top Insights
Allocates 61.3% of revenues to R&D—nearly three times higher than next Spanish competitor and representing 19% annual increase
Achieves 37.5% success rate in investigations, far exceeding the 10.8% industry average, with 8 compounds in clinical trials and 3 approved
Possesses unique collection of 100,000 marine organisms with 700 new chemical entities discovered and 30 new families of compounds identified
Maintains deep commitment to rare diseases with 22 orphan drug designations currently in place worldwide
Named Competitors
Oncology Therapeutics — Large-cap oncology competitor with extensive cancer portfolio
Oncology Portfolio — Major pharma with diverse oncology and immunotherapy offerings